

Supplementary information

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity


In the format provided by the
authors and unedited

a


NK cells Gating Strategy




Foxp3+/Foxp3- cells Gating Strategy




TOX Gating Strategy





pSTAT5 Gating Strategy





b**CT26 TILs Gating Strategy**

c



Figure 6f





Extended Data Figure 1e




Extended Data Figure 1o




Extended Data Figure 1p



Extended Data Figure 8g



Extended Data Figure 8h



Supplementary Figure 1.
a. Gating strategy for NKCs, Foxp3⁺/Foxp3⁻, TOX/TIM3 and pSTAT5 in Figure 6a-b.
b. Gating strategy for NKCs, CD8 T cells and macrophages in Extended Data Figure 8b-e.
c. Full western blot scans with MW markers for Figure 6f, Extended Data Figure 1e, o, and p and Extended Data Figure 8g and h.